A Phase 1 Combined Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6858 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2016
At a glance
- Drugs ASP 6858 (Primary)
- Indications Renal failure
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 19 May 2016 Status changed from recruiting to completed.
- 12 Nov 2015 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
- 06 Oct 2015 Planned number of patients changed from 110 to 118, as reported by ClinicalTrials.gov.